phrykt

Denali Therapeutics Inc. (DNLI): who owns it and who trades it

As of Nov 16, 2026, DNLI insiders reported 7 open-market sales worth $1.3M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ryan J. Watts (CEO), with $581K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Denali Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DNLI

293 funds and institutions reported DNLI shares worth $4.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 10.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

T. Rowe Price Investment Management, Inc.10.2%
BlackRock, Inc.8.8%
Baillie Gifford & Co7.5%
State Street Corp4.4%
Temasek Holdings (Private) Ltd4.4%
Vanguard Portfolio Management LLC4.1%
Vanguard Capital Management LLC4.0%
FMR LLC (Fidelity)2.9%
Goldman Sachs Group Inc2.6%
Geode Capital Management, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
T. Rowe Price Investment Management, Inc.16.18M10.19%$416M+90%
BlackRock, Inc.14.03M8.84%$361M+8%
Baillie Gifford & Co11.96M7.54%$308M-1%
State Street Corp7.05M4.44%$181M+12%
Temasek Holdings (Private) Ltd7.01M4.42%$180MNo change
Vanguard Portfolio Management LLC6.48M4.08%$167M+6%
Vanguard Capital Management LLC6.28M3.95%$161M+2%
FMR LLC (Fidelity)4.54M2.86%$117M-1%
Goldman Sachs Group Inc4.16M2.62%$107M-6%
Geode Capital Management, LLC3.97M2.50%$102M+7%
California State Teachers Retirement System3.91M2.46%$152M+2306%
Holocene Advisors, LP3.91M2.46%$100M+22%
Baker Bros. Advisors LP3.73M2.35%$96M+0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3.16M1.99%$81.3M-29%
T. Rowe Price Associates3.14M1.98%$80.7M+27%
UBS Group AG3.12M1.97%$80.3M+21%
Alliancebernstein L.P.2.98M1.88%$57.3M+3%
Dimensional Fund Advisors LP2.86M1.80%$73.6M+6%
Norges Bank2.82M1.78%$72.7M–
Pictet Asset Management Holding SA2.79M1.76%$71.9M+9%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DNLI insiders reported $0 of open-market purchases and $1.3M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.3M
7 trades, 4 people
Sales under a 10b5-1 plan
25%
Share of sale value
Latest trade
Sep 4, 2026
Filed Sep 9, 2026

Purchases and sales by month

$865K$865KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 4, 2026Peter Scott ChinChief Medical OfficerSale1,654$22.29$36.9KForm 4
Sep 2, 2026Nancy ThornberryDirectorSale plan10,824$22.85$247KForm 4
Sep 2, 2026Nancy ThornberryDirectorSale plan615$23.74$14.6KForm 4
Sep 1, 2026Alexander O. SchuthCOFO and SecretarySale plan2,768$23.44$64.9KForm 4
Aug 11, 2026Alexander O. SchuthCOFO and SecretarySale2,857$25.07$71.6KForm 4
Jan 6, 2026Ryan J. WattsCEOSale35,198$16.50$581KForm 4
Jan 6, 2026Alexander O. SchuthCOFO and SecretarySale17,218$16.50$284KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ryan J. WattsPresident and CEO, Director–$581KJan 6, 2026
Alexander O. SchuthCOFO and Secretary–$421KSep 1, 2026
Nancy ThornberryDirector–$262KSep 2, 2026
Peter Scott ChinChief Medical Officer–$36.9KSep 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DNLI short interest

Moderate short interest. 9.2% of DNLI shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14.69M DNLI shares were sold short, 9.2% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.48M shares, buying them all back would take about 9.9 trading days (days to cover).

Shares short, % of all shares

9.17%May 15Oct 3011.6%

Days to cover

9.9May 15Oct 3019.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.69M9.17%-5%1.48M9.9
Oct 15, 202615.48M9.68%+0%1.92M8.1
Sep 30, 202615.46M9.67%-10%2.02M7.6
Sep 15, 202617.14M10.72%+3%1.43M12.0
Aug 31, 202616.64M10.41%-7%951,21617.5
Aug 14, 202617.96M11.24%+3%1.45M12.4
Jul 31, 202617.43M10.91%+9%1.44M12.1
Jul 15, 202616.04M10.10%+1%1.91M8.4
Jun 30, 202615.95M10.05%+4%2.30M7.0
Jun 15, 202615.41M9.71%+3%1.83M8.4
May 29, 202614.99M9.45%+7%1.87M8.0
May 15, 202614.03M8.84%-5%1.87M7.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Denali Therapeutics company events

Denali Therapeutics filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 28, 2026DealDenali Therapeutics Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company. Filing
  4. Jun 18, 2026AgreementDenali Therapeutics Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher. Filing
  5. Jun 4, 2026VoteReported shareholder vote results. Filing
  6. May 22, 2026AnnouncementShared information with investors. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 3, 2026AgreementEnded an important agreement. Filing
  9. Mar 31, 2026DebtTook on new debt. Filing
  10. Mar 25, 2026AnnouncementShared information with investors. Filing
  11. Feb 26, 2026ResultsReleased financial results. Filing
  12. Jan 6, 2026AnnouncementShared information with investors. Filing
  13. Dec 10, 2025AgreementDenali Therapeutics Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters named therein, relating to the public offering of 9,142,857 shares of the Company’s common stock, par… Filing
  14. Dec 4, 2025AnnouncementDenali provided the following key updates on programs across its development pipeline at its 2025 Investor Day. Filing
  15. Dec 4, 2025AgreementDenali Therapeutics Inc. entered into a synthetic royalty funding agreement with Royalty Pharma plc. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Denali Therapeutics financials

Famous investors that hold DNLI

6 of the 50 well-known investors we track reported holding DNLI in their latest 13F filing. The largest position is Ken Fisher's, worth $50.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 20262.46M$50.9M0.0%+2%
Israel Englander · Millennium ManagementQ3 2026749,575$15.5M0.0%-33%
Ken Griffin · Citadel AdvisorsQ3 2026595,777$12.3M0.0%+790%
Jim Simons · Renaissance TechnologiesQ3 2026218,700$4.5M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202663,692$1.3M0.0%+55%
Steve Cohen · Point72 Asset ManagementQ3 202661,189$1.3M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DNLI in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A12.3%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A12.3%

Questions about Denali Therapeutics Inc. (DNLI) stock

Who owns the most DNLI stock?

The largest reported owner of Denali Therapeutics Inc. (DNLI) is T. Rowe Price Investment Management, Inc., with 10.2% of the company. In total, 293 funds and institutions reported holding DNLI at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are DNLI insiders buying or selling?

In the last 12 months, DNLI insiders reported no open-market purchases and 7 sales worth $1.3M. The latest trade was on Sep 4, 2026. See every trade.

What is the short interest in DNLI?

As of Oct 30, 2026, 14.69M DNLI shares were sold short, 9.2% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.48M shares, buying them all back would take about 9.9 trading days (days to cover). See the history.

Which famous investors hold DNLI?

6 of the 50 well-known investors we track reported DNLI in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $50.9M. See all holders.

Executive pay

Denali Therapeutics's chief executive was paid a total of $4.8M for the year ended Dec 31, 2025, down 28% from $6.6M the year before. In the last 12 months, Denali Therapeutics's executives and directors bought no stock on the open market and sold $1.3M.

Chief executive, total pay$4.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.